Rosenblum M L, Dougherty D V, Reese C, Wilson C B
Cancer Chemother Pharmacol. 1981;6(3):227-35. doi: 10.1007/BF00256975.
A clonogenic cell assay for malignant brain tumors that permits the evaluation of tumor cell sensitivity to BCNU and that correlates with patient response to BCNU has been developed. The potential for a stem cell analysis of human tumors has been demonstrated by studies of the reasons for clinical drug failure, tumor heterogeneity, and age-response relationships. The basic requirements of a stem cell assay include the ability to dissociate representative single cells from solid tumors, to optimize culture conditions, and to characterize the growth of colonies. Exposure of cells to a drug in vitro must be comparable to the in situ situation; possible significant differences between short-term and "continuous" treatment methods are emphasized. Also discussed are criteria for in vitro sensitivity of cells, problems inherent in the "early" evaluation of cultures (at the cell "cluster" stage), and the effects of system errors, which if overcome should lead to the development of analytic methods with a maximum sensitivity and predictive value.
已开发出一种用于恶性脑肿瘤的克隆形成细胞测定法，该方法可评估肿瘤细胞对卡氮芥（BCNU）的敏感性，并与患者对BCNU的反应相关。对临床药物失效原因、肿瘤异质性和年龄反应关系的研究证明了对人类肿瘤进行干细胞分析的可能性。干细胞测定的基本要求包括从实体瘤中分离出具有代表性的单细胞的能力、优化培养条件以及对集落生长进行表征。细胞在体外接触药物的情况必须与原位情况相当；强调了短期和“连续”治疗方法之间可能存在的显著差异。还讨论了细胞体外敏感性的标准、培养物“早期”（细胞“簇”阶段）评估中固有的问题以及系统误差的影响，若克服这些问题应能开发出具有最大敏感性和预测价值的分析方法。
